The Senate Committee on Health, Education, Labor and Pensions, chaired by Sen. Bill Cassidy (R-LA), examined responses from mifepristone manufacturers Danco Laboratories, GenBioPro, and Evita Solutions regarding FDA REMS program requirements. Court actions in 2023 addressed mailing restrictions on the drug following the 2022 Dobbs decision. Available sources, both rated right-leaning, provide the sole documented basis for reported findings.